Overview

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Phase:
Phase 1
Details
Lead Sponsor:
SciTech Development, LLC
Collaborator:
Rush University Medical Center
Treatments:
Fenretinide
Retinamide
Tretinoin